FY2025 EPS Estimates for Medifast Decreased by Analyst

Medifast Inc (NYSE:MED) – Equities research analysts at Zacks Research cut their FY2025 EPS estimates for Medifast in a research report issued to clients and investors on Monday, November 24th. Zacks Research analyst Team now forecasts that the specialty retailer will post earnings of ($1.08) per share for the year, down from their prior estimate of $0.02. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at $0.04 EPS, Q3 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.07) EPS.

MED has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a report on Wednesday, October 8th. Wall Street Zen cut Medifast from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $16.50.

Medifast Stock Up 0.1%

Shares of Medifast stock opened at $10.99 on Thursday. Medifast has a 12-month low of $10.36 and a 12-month high of $21.98. The company has a market capitalization of $120.74 million, a price-to-earnings ratio of 34.33 and a beta of 0.82. The firm’s 50-day moving average price is $12.47 and its two-hundred day moving average price is $13.35.

Medifast (NYSE:MED) last issued its quarterly earnings data on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.20). Medifast had a return on equity of 2.00% and a net margin of 0.76%.The business had revenue of $89.41 million during the quarter, compared to analyst estimates of $84.10 million. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Medifast by 14.2% during the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock valued at $6,186,000 after acquiring an additional 56,174 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Medifast by 6.6% in the 2nd quarter. Acadian Asset Management LLC now owns 411,101 shares of the specialty retailer’s stock worth $5,769,000 after purchasing an additional 25,378 shares in the last quarter. Lido Advisors LLC bought a new position in Medifast in the third quarter valued at about $4,521,000. Dimensional Fund Advisors LP boosted its stake in shares of Medifast by 19.6% during the third quarter. Dimensional Fund Advisors LP now owns 298,369 shares of the specialty retailer’s stock valued at $4,079,000 after purchasing an additional 48,967 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Medifast by 132.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer’s stock valued at $3,580,000 after purchasing an additional 151,434 shares in the last quarter. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.